Xu, Y., Li, D., Wang, N., Ge, B., Meng, C., Zhao, M., . . . Ye, H. (2025). miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting. Clinical Epigenetics, 17(1), 1. https://doi.org/10.1186/s13148-025-01823-1
Chicago-referens (17:e uppl.)Xu, Yilan, et al. "MiR-182 Promoter Hypermethylation Predicts the Better Outcome of AML Patients Treated with AZA + VEN in a Real-world Setting." Clinical Epigenetics 17, no. 1 (2025): 1. https://doi.org/10.1186/s13148-025-01823-1.
MLA-referens (9:e uppl.)Xu, Yilan, et al. "MiR-182 Promoter Hypermethylation Predicts the Better Outcome of AML Patients Treated with AZA + VEN in a Real-world Setting." Clinical Epigenetics, vol. 17, no. 1, 2025, p. 1, https://doi.org/10.1186/s13148-025-01823-1.
